June 23, 2020 / 11:36 AM / 12 days ago

BRIEF-Myovant Announces Positive Results From Study Evaluating Once-Daily Relugolix Combination Therapy

June 23 (Reuters) - Myovant Sciences Ltd:

* MYOVANT SCIENCES ANNOUNCES POSITIVE RESULTS FROM SECOND PHASE 3 STUDY EVALUATING ONCE-DAILY RELUGOLIX COMBINATION THERAPY IN WOMEN WITH ENDOMETRIOSIS

* MYOVANT SCIENCES LTD - CO-PRIMARY ENDPOINTS MET

* MYOVANT SCIENCES LTD - ACHIEVED ALL SEVEN KEY SECONDARY ENDPOINTS WITH A GENERALLY WELL-TOLERATED SAFETY PROFILE

* MYOVANT SCIENCES LTD - RELUGOLIX COMBINATION THERAPY WAS GENERALLY WELL-TOLERATED WITH MINIMAL BONE MINERAL DENSITY LOSS OVER 24 WEEKS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below